Decline in Over-the-Counter Naloxone Sales After Initial Increase
Initial increases in over-the-counter naloxone sales following its 2023 availability were short-lived, with sales declining rapidly and remaining low, impacting efforts to combat the opioid crisis.
Following the nationwide rollout of over-the-counter naloxone in September 2023, a significant initial surge in sales was observed, but this enthusiasm quickly waned over the subsequent months, according to a recent study conducted by RAND Corporation. Naloxone, a critical medication capable of reversing opioid overdoses—including those involving fentanyl—is paramount in combating the ongoing opioid crisis.
In the first month after the medication became available without a prescription, sales peaked, but then rapidly declined and stabilized through most of 2024. Interestingly, a slight uptick was noted in August 2024. Despite the increased accessibility, the total over-the-counter sales remained surprisingly low—only about 7.5% of the quantity sold through prescriptions, highlighting limited adoption.
Research led by Bradley D. Stein analyzed sales data across various states from September 2023 to September 2024. The findings revealed considerable geographic variation, with Western states demonstrating higher sales. On average, 396 units per million residents were sold over-the-counter during this period. The cost for a two-pack of nasal spray naloxone averaged nearly $45, which may have influenced purchasing behavior.
Compared to pharmacy-dispensed and free program-distributed naloxone, over-the-counter sales were modest. Pharmacy-based sales averaged over 7,000 units per million residents in 2023, while free distribution programs accounted for roughly 12,000 units per million residents from August 2022 to August 2024. The high price of over-the-counter naloxone is believed to be a key factor limiting its use.
Despite the low sales volume, the increased availability of naloxone has been associated with a notable reduction in opioid overdose deaths in 2023—the first decline in many years. Experts suggest that further measures, such as improving insurance coverage and increasing retail visibility, could help expand access and save more lives.
The study emphasizes the need to understand factors affecting demand, including the potential impact of insurance policies and retail placement strategies, to optimize the distribution of this life-saving medication.
Source: https://medicalxpress.com/news/2025-09-counter-sales-overdose-reversal-drug.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
The Impact of Microplastics on Brain Health: What We Know So Far
Emerging research indicates microplastics are found in human brains, but their health effects remain uncertain. Learn about recent studies and the need for precautionary action against plastic pollution's impact on brain health.
New DIAL Syndrome Identified: Linking DNA Repair Defects to Childhood Cancer and Chemotherapy Response
Scientists have discovered DIAL syndrome, a new hereditary disorder caused by mutations in the DIAPH1 gene, linking faulty DNA repair to increased childhood cancer risk and chemotherapy sensitivity. Early diagnosis could improve personalized treatment strategies.
Study Reveals Strong Connection Between Street Sweeps, Overdose, and Systemic Harm
A recent study uncovers the harmful impact of street sweeps on homeless individuals, linking belongings confiscation to increased overdose risks, violence, and barriers to essential services in Vancouver.
Germany's BioNTech Acquires CureVac to Accelerate Cancer Research Using mRNA Technology
Germany's BioNTech is acquiring CureVac for $1.25 billion to strengthen its mRNA technology platform and accelerate the development of innovative cancer immunotherapies, marking a significant move in biotech research.